乌司奴单抗治疗期间银屑病相关皮肤微生物组的纵向研究:一项随机3b期临床试验
该研究在114例斑块状银屑病患者中,于乌司奴单抗治疗前及治疗期间,对皮损及邻近非皮损部位六个解剖部位的皮肤菌群进行16S rRNA基因测序。结果显示治疗前皮损与非皮损菌群多样性及组成仅存在部位特异性微小差异;治疗期间两组菌群趋异、部位分散度增加;复发皮损菌群与初始皮损不重叠;斑块状银屑病似乎不与特定微生物或菌群多样性相关。
要点
- 治疗前皮损与非皮损菌群多样性和组成仅见部位特异性微小差异。
- 治疗期间皮损与非皮损菌群趋异,部位分散度增加,反映皮肤部位特异性。
- 复发皮损菌群与初始皮损菌群不重叠,提示定植模式不同。
核心结论
- 斑块状银屑病似乎不与特定微生物或菌群多样性相关,但该大型数据集揭示了与疾病部位、初发与复发皮损及抗IL-12/23治疗相关的菌群变异。
研究设计与样本
- 随机3b期临床试验中,对114例斑块状银屑病患者在乌司奴单抗治疗前及治疗期间,从六个解剖部位采集皮肤拭子并测序细菌16S核糖体RNA基因。
主要发现
- 治疗前皮损与非皮损皮肤之间微生物多样性和组成存在部位特异性微小差异。
- 治疗期间皮损与非皮损皮肤内微生物群落趋异,身体部位分散度增加,反映皮肤部位特异性。
- 皮损治疗前菌群异质性大于非皮损皮肤,且随治疗进展变异增加。
- 复发皮损定植菌群与治疗前皮损菌群不重叠,提示初发与复发皮损定植模式不同。
关键数值与推荐
- 共纳入114例患者,从六个解剖部位采集皮肤拭子样本。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plaque psoriasis, a chronic inflammatory disease primarily affecting the skin, is thought to have a multifactorial etiology, including innate immune system dysregulation, environmental triggers, and genetic susceptibility. We sought to further understand the role of skin microbiota in psoriasis pathogenesis, as well as their response to therapy. We systematically analyzed dynamic microbiota colonizing psoriasis lesions and adjacent nonlesional skin in 114 patients prior to and during ustekinumab treatment in a phase 3b clinical trial. By sequencing the bacterial 16S ribosomal RNA gene from skin swab samples obtained at six anatomical sites, we identified minor, site-specific differences in microbial diversity and composition between pretreatment lesional and nonlesional skin. During therapy, microbial communities within lesional and nonlesional skin diverged, and body-site dispersion increased, reflecting microbial skin site-specificity. Microbiota demonstrated greater pretreatment heterogeneity in psoriatic lesions than in nonlesional skin, and variance increased as treatment progressed. Microbiota colonizing recurrent lesions did not overlap with pretreatment lesional microbiota, suggesting colonization patterns varied between initial and recurrent psoriatic lesions. While plaque psoriasis does not appear to be associated with specific microbes and/or microbial diversity, this large dataset provides insight into microbial variation associated with (i) disease in different body locations, (ii) initial versus recurrent lesions, and (iii) anti-IL12/23 therapy.
引用
- Loesche MA, Farahi K, Capone K, et al. Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. J Invest Dermatol. 2018. PMID: 29559344. doi:10.1016/j.jid.2018.03.1501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。